PinkDx, Inc., a Daly City, CA-based company focused on positively impacting the health of women throughout their life journey, raised $40m in Series A financing.
The round was co-led by Catalio Capital Management, LP, and The Production Board. Other investors include Mountain Group Partners, Byers Capital and Mayo Clinic.
The company will use the funds to test development, focusing initially on gynecological cancers.
Led by Bonnie Anderson, cofounder, chairwoman and chief executive officer, and CSO Giulia C. Kennedy, Ph.D., and chief financial officer and chief business officer Tim McMeekan, PinkDx is an early-stage company focused on addressing the medical problems that women face by applying scientific approaches to resolve them and providing answers that have an immediate, positive impact on their lives. The company’s first indication will focus on overcoming diagnostic challenges for women who present with general symptoms that could signal a gynecological cancer.
PinkDx also announced that Alison Cowan, M.D., M.S.C.R., has joined the company as chief medical officer and will guide the clinical development of PinkDx’s solutions. Prior to joining PinkDx, Dr. Cowan served as head of Medical Affairs for Mirvie and before that as medical director for Hologic’s Diagnostics division. She has 14 years of clinical experience in both academic and community settings and maintains a clinical practice as an OB/GYN hospitalist in Colorado. Dr. Cowan received her medical degree and master’s in clinical research from Emory University and completed her OB/GYN residency at Northwestern University.
FinSMEs
25/04/2024